BofA raised the firm’s price target on Novo Nordisk (NVO) to DKK 340 from DKK 315 and keeps a Neutral rating on the shares. Many investors consider the CagriSema launch at the end of 2026 key to growth in FY27-28, but the firm is more cautious on it than consensus given concerns about limited differentiation and that Novo is losing critical mass to Eli Lilly (LLY), the analyst noted.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk’s Stock Surges Amid Drug Breakthrough
- Trump Weekly: White House postpones healthcare proposal after backlash
- Novo Nordisk price target lowered to $54 from $60 at Goldman Sachs
- As America’s Job Market Cracks, Here Are the Layoff Announcements You Can’t Ignore
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!